A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 54
- Registration Number
- NCT00655668
- Locations
- 🇫🇷
CHRU Hôpitaux de Brabois - Hématologie, Vandoeuvre Les Nancy, Rue Morvan Cedex, France
🇫🇷Hôpital Purpan, Toulouse, France
🇧🇪Institute Jules Bordet, Bruxelles, Belgium
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 31
- Registration Number
- NCT00652626
- Locations
- 🇺🇸
Palm Springs Research Institute, Hialeah, Florida, United States
🇺🇸Sutter East Bay Hospitals, Berkeley, California, United States
🇺🇸Pharma Resource, East Providence, Rhode Island, United States
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 27
- Registration Number
- NCT00635284
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 86
- Registration Number
- NCT00629473
- Locations
- 🇦🇺
Mater Adult Hospital, South Brisbane, Queensland, Australia
🇦🇺The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 330
- Registration Number
- NCT00622336
- Locations
- 🇷🇺
Nizhny Novgorod Clinical Hospital n.a.Semashko, Nizhny Novgorod, Russian Federation
🇺🇦Kharkov Postgraduate Medical Academy Kharkov Regional Clinical, Kharkov, Ukraine
🇺🇦Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
- Conditions
- Interventions
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT00596999
- Locations
- 🇺🇸
Louisiana State University Children's Hospital, New Orleans, Louisiana, United States
Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma
- Conditions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT00555100
- Locations
- 🇯🇵
Keio University Hospital, Tokyo, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata, Japan
🇯🇵National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 637
- Registration Number
- NCT00547651
- Locations
- 🇺🇸
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
🇺🇸Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
🇺🇸Cancer Care Associates of Fresno Medical Group, Inc., Fresno, California, United States
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1052
- Registration Number
- NCT00540514
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT00537511
- Locations
- 🇺🇸
Pennsylvania State University, Hershey, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology, Cleveland, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States